French authorities approve national reimbursement of orkambi (lumacaftor/ivacaftor) for eligible people ages two and older with cystic fibrosis

Vertex pharmaceuticals incorporated announced that the french authorities (comitÉ Économique des produits de santÉ, or ceps) have approved national reimbursement of orkambi® (lumacaftor/ivacaftor) for people ages two and older with cystic fibrosis (cf) who have two copies of the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene. orkambi will be available for all eligible patients once the agreement has been published in the french official journal. in france, orkambi has been available to eligible patients ages 12 and older since december 2015 through a temporary use authorization (autorisations temporaires d’utilisation, or atu) and a post-atu interim access program. in addition to providing reimbursement for patients ages 12 and older, today’s agreement also enables people ages 2 to 11 years to access orkambi in france for the first time. all those who are currently prescribed orkambi through the atu will now receive it through this new agreement. vertex’s cf medicines are reimbursed in 21 countries around the world, including recent agreements in australia, england and spain.
VRTX Ratings Summary
VRTX Quant Ranking